There are concerns about arterial thromboembolic event after intravitreal injection of bevacizumab or ranibizumab. Motivated by the fact that D-dimer was a sensitive biomarker for thromboembolism, we evaluated serum D-dimer levels in patients with age-related macular degeneration (AMD) after intravitreal injection of bevacizumab and ranibizumab.
Methods:
In this prospective, nonrandomized, uncontrolled study, 122 patients (122 eyes) with AMD were enrolled. Sixty-two eyes received intravitreal injections of bevacizumab and 60 eyes received intravitreal injections of ranibizumab monthly for 3 months. Serum D-dimer levels were measured in patients before intravitreal injection and 1 day, 1 week, 1 month, and 3 months thereafter.
Results:
Serum D-dimer levels were not significantly altered following injection of either bevacizumab or ranibizumab. Subgroup analysis for patients at risk for thromboembolic events revealed that serum D-dimer levels showed no significant change after injection of ranibizumab. However, D-dimer levels significantly increased at 1 day (P=0.041) and 1 week (P=0.022) after injection of bevacizumab.
Conclusions:
Serum D-dimer levels were not changed after injection with either bevacizumab or ranibizumab. In subgroup analysis, bevacizumab injection in patients at risk of thromboembolism increased serum D-dimer levels.
Get full access to this article
View all access options for this article.
References
1.
RosenfeldP.J., BrownD.M., HeierJ.S., BoyerD.S., KaiserP.K., ChungC.Y., and KimR.Y.Ranibizumab for neovascular age-related macular degeneration. N. Engl. J. Med., 355:1419–1431, 2006.
2.
SchmuckerC., EhlkenC., HansenL.L., AntesG., AgostiniH.T., and LelgemannM.Intravitreal bevacizumab (Avastin) vs. ranibizumab (Lucentis) for the treatment of age-related macular degeneration: a systematic review. Curr. Opin. Ophthalmol., 21:218–226, 2010.
3.
BrownD.M., KaiserP.K., MichelsM., SoubraneG., HeierJ.S., KimR.Y., SyJ.P., and SchneiderS.Ranibizumab versus verteporfin for neovascular age-related macular degeneration. N. Engl. J. Med., 355:1432–1444, 2006.
4.
SchoutenJ.S., La HeijE.C., WebersC.A., LundqvistI.J., and HendrikseF.A systematic review on the effect of bevacizumab in exudative age-related macular degeneration. Graefes Arch. Clin. Exp. Ophthalmol., 247:1–11, 2009.
5.
FerraraN., HillanK.J., GerberH.P., and NovotnyW.Discovery and development of bevacizumab, an anti-VEGF antibody for treating cancer. Nat. Rev. Drug Discov., 3:391–400, 2004.
6.
FerraraN., DamicoL., ShamsN., LowmanH., and KimR.Development of ranibizumab, an anti-vascular endothelial growth factor antigen binding fragment, as therapy for neovascular age-related macular degeneration. Retina., 26:859–870, 2006.
7.
CsakyK., and DoD.V.Safety implications of vascular endothelial growth factor blockade for subjects receiving intravitreal anti-vascular endothelial growth factor therapies. Am. J. Ophthalmol., 148:647–656, 2009.
8.
Schmidt-ErfurthU.Clinical safety of ranibizumab in age-related macular degeneration. Expert. Opin. Drug Saf., 9:149–165, 2010.
9.
KilickapS., AbaliH., and CelikI.Bevacizumab, bleeding, thrombosis, and warfarin. J. Clin. Oncol., 21:3542, 2003; author reply 3543.
10.
UetaT., YanagiY., TamakiY., and YamaguchiT.Cerebrovascular accidents in ranibizumab. Ophthalmology., 116:362, 2009.
11.
AlexanderS.L., Linde-ZwirbleW.T., WertherW., DepperschmidtE.E., WilsonL.J., PalankiR., SarojN., ButterworthS.L., and IanchulevT.Annual rates of arterial thromboembolic events in medicare neovascular age-related macular degeneration patients. Ophthalmology., 114:2174–2178, 2007.
12.
MannucciP.Venous thrombosis: the history of knowledge. Pathophysiol. Haemost. Thromb., 32:209–212, 2002.
13.
ThorneycroftI.H., and GoldzieherJ.W.Venous thromboembolism: a review. J. Reprod. Med., 48(11 Suppl):911–920, 2003.
14.
LippiG., CervellinG., FranchiniM., and FavaloroE.J.Biochemical markers for the diagnosis of venous thromboembolism: the past, present and future. J. Thromb. Thrombolysis., 30:459–471, 2010.
15.
HargettC.W., and TapsonV.F.Clinical probability and D-dimer testing: how should we use them in clinical practice?. Semin. Respir. Crit. Care Med., 29:15–24, 2008.
16.
TripodiA.D-dimer testing in laboratory practice. Clin. Chem., 57:1256–1262, 2011.
17.
CosmiB., and PalaretiG.Update on the predictive value of D-dimer in patients with idiopathic venous thromboembolism. Thromb. Res., 125(Suppl 2):S62–S65, 2010.
18.
VerhovsekM., DouketisJ.D., YiQ., ShrivastavaS., TaitR.C., BaglinT., PoliD., and LimW.Systematic review: D-dimer to predict recurrent disease after stopping anticoagulant therapy for unprovoked venous thromboembolism. Ann. Intern. Med., 149:481–490, W494, 2008.
19.
Brill-EdwardsP., and LeeA.D-dimer testing in the diagnosis of acute venous thromboembolism. Thromb. Haemost., 82:688–694, 1999.
20.
WadaH., KobayashiT., AbeY., HatadaT., YamadaN., SudoA., UchidaA., and NoboriT.Elevated levels of soluble fibrin or D-dimer indicate high risk of thrombosis. J. Thromb. Haemost., 4:1253–1258, 2006.
21.
LoweG.D.Can haematological tests predict cardiovascular risk?. The 2005 Kettle Lecture. Br. J. Haematol., 133:232–250, 2006.
22.
BakriS.J., SnyderM.R., ReidJ.M., PulidoJ.S., EzzatM.K., and SinghR.J.Pharmacokinetics of intravitreal ranibizumab (Lucentis). Ophthalmology., 114:2179–2182, 2007.
23.
BakriS.J., SnyderM.R., ReidJ.M., PulidoJ.S., and SinghR.J.Pharmacokinetics of intravitreal bevacizumab (Avastin). Ophthalmology., 114:855–859, 2007.
24.
NomotoH., ShiragaF., KunoN., KimuraE., FujiiS., ShinomiyaK., NugentA.K., HirookaK., and BabaT.Pharmacokinetics of bevacizumab after topical, subconjunctival, and intravitreal administration in rabbits. Invest. Ophthalmol. Vis. Sci., 50:4807–4813, 2009.
25.
KimH., RobinsonS.B., and CsakyK.G.FcRn receptor-mediated pharmacokinetics of therapeutic IgG in the eye. Mol. Vis., 15:2803–2812, 2009.
26.
CarneiroA.M., CostaR., FalcaoM.S., BarthelmesD., MendoncaL.S., FonsecaS.L., GoncalvesR., GoncalvesC., Falcao-ReisF.M., and SoaresR.Vascular endothelial growth factor plasma levels before and after treatment of neovascular age-related macular degeneration with bevacizumab or ranibizumab. Acta Ophthalmol., 90:e25–e30, 2011.
27.
MeyerC.H., and HolzF.G.Preclinical aspects of anti-VEGF agents for the treatment of wet AMD: ranibizumab and bevacizumab. Eye (Lond)., 25:661–672, 2011.
28.
MatsuyamaW., HashiguchiT., MizoguchiA., IwamiF., KawabataM., ArimuraK., and OsameM.Serum levels of vascular endothelial growth factor dependent on the stage progression of lung cancer. Chest., 118:948–951, 2000.
29.
TsengC.S., LoH.W., TengH.C., LoW.C., and KerC.G.Elevated levels of plasma VEGF in patients with dengue hemorrhagic fever. FEMS Immunol. Med. Microbiol., 43:99–102, 2005.
30.
HuC.C., HoJ.D., and LinH.C.Neovascular age-related macular degeneration and the risk of stroke: a 5-year population-based follow-up study. Stroke., 41:613–617, 2010.
31.
SunC., KleinR., and WongT.Y.Age-related macular degeneration and risk of coronary heart disease and stroke: the Cardiovascular Health Study. Ophthalmology., 116:1913–1919, 2009.
32.
WongT.Y., KleinR., SunC., MitchellP., CouperD.J., LaiH., HubbardL.D., and SharrettA.R.Age-related macular degeneration and risk for stroke. Ann. Intern. Med., 145:98–106, 2006.
33.
MartinD.F., MaguireM.G., YingG.S., GrunwaldJ.E., FineS.L., and JaffeG.J.Ranibizumab and bevacizumab for neovascular age-related macular degeneration. N. Engl. J. Med., 364:1897–1908, 2011.
34.
TolentinoM.Systemic and ocular safety of intravitreal anti-VEGF therapies for ocular neovascular disease. Surv. Ophthalmol., 56:95–113, 2011.
35.
SchmuckerC., EhlkenC., AgostiniH.T., AntesG., RueckerG., LelgemannM., and LokeY.K.A safety review and meta-analyses of bevacizumab and ranibizumab: off-label versus goldstandard. PloS One., 7:e42701, 2012.
36.
WellsP.S., AndersonD.R., RodgerM., ForgieM., KearonC., DreyerJ., KovacsG., MitchellM., LewandowskiB., and KovacsM.J.Evaluation of D-dimer in the diagnosis of suspected deep-vein thrombosis. N. Engl. J. Med., 349:1227–1235, 2003.
